Every 8-K that Quince (QNCX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow QNCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNCX filings page.
Quince Therapeutics, Inc. (QNCX) reports that Nasdaq has notified the company it is not in compliance with Nasdaq Global Select Market Listing Rule 5450(b)(1)(A) because its stockholders’ equity was ($35,324,000) as of June 30, 2026, below the required $10,000,000 minimum.
The notice does not immediately affect trading, and the common stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX. Quince has 45 days, until October 15, 2026, to submit a plan to regain compliance, with a potential extension of up to 180 days, to February 27, 2027, if Nasdaq accepts the plan. The company is evaluating alternatives and has also submitted an initial listing application that, if approved along with required stockholder matters, would support a transfer to the Nasdaq Capital Market under the new name IRulya Therapeutics Inc. and the symbol IRLA.
Quince Therapeutics, Inc. (QNCX) reported a leadership change in which President Charles Ryan and the company determined that his last day of employment will be September 8, 2026. In connection with the end of his service as President, he will be eligible for severance benefits under his existing Executive Change in Control and Severance Agreement dated September 1, 2023, as previously described in Quince Therapeutics’ definitive proxy statement on Schedule 14A filed with the SEC on August 25, 2026.
Quince Therapeutics, Inc. is calling a special stockholder meeting to approve the issuance of common shares tied to its Series C Non-Voting Convertible Preferred Stock, related warrants, and options. These issuances will represent more than 20% of existing common stock and, together with management and board changes, may result in a change of control under Nasdaq Listing Rules 5635(a) and 5635(b). Stockholders are also being asked to approve issuances related to a May 2026 private placement under Nasdaq Listing Rule 5635(d).
Quince provides unaudited pro forma condensed consolidated financial information as of June 30, 2026, illustrating the balance sheet impact of automatically converting all Series C Preferred Stock into common stock and reclassifying warrant liabilities to equity after stockholder approval. On a pro forma basis, total assets remain at $123,995 thousand, but warrant liabilities of $6,292 thousand and Series C Preferred Stock of $143,811 thousand are eliminated, and additional paid-in capital increases by $150,092 thousand, shifting total stockholders’ equity from a deficit of $(35,324) thousand to positive equity of $114,779 thousand. Common shares outstanding would increase from 1,017,063 to 12,004,791 after the conversion.
Quince Therapeutics reported second-quarter 2026 results highlighted by the completed acquisition of Orphai Therapeutics, which added LAM-001, an inhaled rapamycin candidate for multiple serious pulmonary diseases, to its pipeline. The company has initiated a Phase 2b trial of LAM-001 for pulmonary hypertension associated with interstitial lung disease (PH-ILD) with data anticipated in the first quarter of 2028, and a Phase 2 trial in bronchiolitis obliterans syndrome (BOS) with data expected in the first quarter of 2027, and plans a Phase 2 study in sarcoidosis-associated pulmonary hypertension (SAPH) in late 2026.
To fund these programs, Quince closed a private placement that generated $115 million in gross upfront proceeds and $103.6 million in net proceeds, with up to an additional $83 million possible upon warrant exercises. Cash and cash equivalents were $116 million as of June 30, 2026, and the company expects this to fund operations through the end of 2028. The quarter included significant non-recurring charges: $59.0 million of acquired in-process R&D and a $67.8 million intangible asset impairment (year-to-date), as well as a sharp increase in G&A expenses driven by $9.1 million in non-cash stock-based compensation and $4.4 million in professional fees. Net loss for the quarter was $75.5 million (or $12.31 per share).
Quince Therapeutics announced that Chief Executive Officer, Chief Medical Officer and director Dirk Thye and Chief Operating, Business and Compliance Officer Brendan Hannah have tendered conditional resignations. Their departures would become effective two business days after the conclusion of a Special Meeting of Stockholders anticipated on September 25, 2026, contingent on stockholder approval of three proposals: the Conversion Proposal, Minimum Price Proposal and Authorized Share Proposal.
Subject to the same effective time, the board conditionally appointed Brigette Roberts as Chief Executive Officer and Principal Executive Officer, John Militello as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Keith R. Fandrick as Chief Operating Officer. Thye and Hannah will remain eligible for previously disclosed retention bonuses and severance if employed through the Special Meeting date. The board approved reducing its size from five to four directors upon Thye’s resignation and intends to add an independent director.
Quince Therapeutics filed Amendment No. 2 to update prior disclosure on its acquisition of Orphai Therapeutics. The amendment adds Orphai’s audited 2024–2025 financial statements, Q1 2026 interim results, unaudited pro forma combined financial information, and expanded business and risk-factor information for the combined company.
After the May 2026 acquisition, Quince is focused on serious pulmonary diseases led by inhaled rapamycin candidate LAM-001. In connection with the transaction, it received $115 million in upfront gross proceeds and may receive up to approximately $72 million more from certain warrants, plus up to $11 million from warrants issued to former Orphai stockholders. LAM-001 is in a 75-patient Phase 2b PH-ILD trial with data expected in Q1 2028, a fully enrolled Phase 2 BOS trial with top-line data expected in Q1 2027, and a planned Phase 2 SAPH study starting in late 2026 with data expected in Q4 2028.
LAM-001 has Orphan Drug Designation in the United States for BOS, sarcoidosis, pulmonary arterial hypertension and lymphangioleiomyomatosis, and in the European Union for BOS and lymphangioleiomyomatosis. Early Phase 1 and 2 studies showed clinically relevant improvements in pulmonary endpoints and low blood rapamycin concentrations around 1 ng/ml, and Quince intends to develop LAM-001 under the 505(b)(2) regulatory pathway while legacy A-T program eDSP has been discontinued after a Phase 3 trial missed its primary endpoints.
Quince Therapeutics, Inc. filed an amended report to correct its description of a previously approved reverse stock split. Stockholders had authorized a reverse split within a wide range, and the board set the final ratio at 1-for-20.
The Certificate of Amendment was filed on June 26, 2026 and the reverse split becomes effective at 11:59 p.m. Eastern Time on June 29, 2026, with split-adjusted trading on the Nasdaq Global Select Market starting June 30, 2026. Each 20 shares of common stock will be combined into 1 share, with fractional shares rounded up.
Immediately before the split there were 19,559,257 shares of common stock outstanding; immediately after effectiveness there will be approximately 977,963 shares outstanding. The split affects all holders uniformly and does not change percentage ownership, rights, or preferences. Options and warrants are proportionally adjusted, and the stock will trade under a new CUSIP while keeping the symbol QNCX.
Quince Therapeutics, Inc. approved and implemented a 1-for-20 reverse stock split of its common stock. The company filed a Certificate of Amendment in Delaware effective at 11:59 p.m. Eastern Time on June 29, 2026, and its shares will begin trading on a split-adjusted basis on June 30, 2026.
Every twenty shares of issued and outstanding common stock will be combined into one share, leaving stockholder ownership percentages generally unchanged, except that fractional shares will be settled in cash. Shares outstanding will decline from 19,559,257 immediately before the split to approximately 977,963 after the split. The stock will continue trading under the symbol QNCX with a new CUSIP number 22053A305.
Quince Therapeutics, Inc. reported voting results from its annual stockholder meeting held online on June 11, 2026. Holders of 6,255,339 shares of common stock, representing approximately 38.37% of eligible shares, were present virtually or by proxy.
Stockholders elected Class I director June Bray to serve until the 2029 annual meeting, approved an amendment to the certificate of incorporation authorizing a reverse stock split in a range from 1-for-10 to 1-for-100 at the board’s discretion, and ratified BDO USA, P.C. as independent registered accounting firm for the fiscal year ending December 31, 2026.
Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and approved the potential adjournment or postponement of the annual meeting to permit further proxy solicitation if necessary.
Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards. Nasdaq staff reviewed the company’s Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, and determined that Quince now meets Nasdaq Listing Rule 5450(b)(1)(A).
This closes a prior deficiency notice issued on March 17, 2026, when Quince had failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed and the company remains listed on the Nasdaq Global Select Market.
Quince Therapeutics, Inc. filed an amendment to its recent report to replace the LAM-001 Phase 2a press release exhibit and correct two pulmonary vascular resistance (PVR) percentages in the efficacy table from 35.3% and 28.1% to -35.3% and -28.1%. No other changes were made.
The updated Exhibit 99.2 describes a 24-week, 10-patient, open-label Phase 2a study of inhaled LAM-001 in pulmonary arterial hypertension and PH-ILD as add-on therapy. Among six evaluable patients, six-minute walk distance improved by 81.3 meters, with a 67.4-meter gain in the PH-ILD subgroup, alongside meaningful reductions in PVR, NT-proBNP and gains in lung function.
All evaluable patients improved from Functional Class III to II by Week 24, and LAM-001 was generally well tolerated on top of standard-of-care therapies. Based on these data, Quince plans a Phase 2b PH-ILD trial starting mid-2026 and additional Phase 2 studies in BOS and SAPH.
Quince Therapeutics completed the acquisition of Orphai Therapeutics in a stock‑for‑stock merger and simultaneously arranged a large private financing to refocus the company on rare pulmonary diseases. Orphai holders received 3,258,517 Quince common shares and 67,101.235 Series C non‑voting convertible preferred shares, plus options and replacement warrants.
The company agreed to sell 144,200.633 additional Series C preferred shares and Financing Warrants to purchase 72,100.322 Series C preferred shares for about $115 million upfront and up to roughly $72 million more if the warrants are fully exercised. After the deal and Financing, Quince pre‑transaction holders would own about 6.9% of common stock, Orphai holders 31.9%, and new investors 61.2% on a fully diluted basis, while management expects cash runway through the end of 2028 to advance LAM‑001 through multiple Phase 2 milestones.
Quince Therapeutics, Inc. reports that Nasdaq has informed the company it has regained compliance with the Nasdaq Global Select Market minimum bid price requirement under Listing Rule 5450(a)(1). The company’s common stock closed at $1.00 or more for 10 consecutive business days from April 13 through April 24, 2026.
The company remains out of compliance with Nasdaq’s market value of listed securities requirement under Listing Rule 5450(b)(2)(A), which requires at least $50,000,000. Quince has until September 14, 2026 to regain compliance with this MVLS requirement, and there is no assurance it will do so or maintain compliance with other listing standards.
Quince Therapeutics, Inc. reported that its Board of Directors increased its size to four members and appointed June Bray as a Class I independent director effective April 22, 2026. She will serve until the 2026 Annual Meeting of Stockholders, or earlier if she departs the role.
Bray has been designated an independent director under Nasdaq rules and will serve on the Nominating & Governance, Audit, and Compensation Committees. Under the company’s Outside Director Compensation Policy, she will receive a $38,000 annual cash retainer for Board service, plus annual retainers of $7,500 for Nominating & Governance, $5,500 for Audit, and $4,000 for Compensation Committee work, without an option grant at appointment. She will also enter into the company’s standard indemnification agreement for directors.
Quince Therapeutics, Inc. is implementing a reverse stock split of its common stock at a 1-for-10 ratio. Every ten shares will be automatically combined into one share, with no change to the $0.001 par value or basic rights of the common stock.
The reverse split becomes effective at 11:59 pm Eastern Time on April 10, 2026, and the shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market on April 13, 2026 under the same symbol QNCX but a new CUSIP 22053A206. Immediately after the split, approximately 16,300,795 shares of common stock will be issued and outstanding. Fractional shares will not be issued; affected stockholders will receive cash in lieu of fractional shares.
Quince Therapeutics, Inc. has eliminated its loan obligations to the European Investment Bank by paying EUR 4,800,000, or approximately $5.5 million, on March 27, 2026. This payment settled outstanding EIB debt of approximately $16.4 million as of that date, and all obligations under the finance and guarantee agreements were fully satisfied and discharged.
The company describes this settlement as a material milestone that removes a significant debt overhang while it continues a corporate restructuring and an evaluation of strategic alternatives, including potential merger, reverse merger, asset sale, or other strategic transactions aimed at maximizing shareholder value.
Quince Therapeutics, Inc. has received two deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Global Select Market. Nasdaq notified the company that its common stock failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, giving Quince until September 14, 2026 to regain compliance by maintaining a closing bid of at least $1.00 for at least ten consecutive business days.
The company also received a notice that its market value of listed securities has been below the required $50,000,000 for 30 consecutive business days, with the same compliance deadline and ten-day cure standard. Quince may seek to transfer to the Nasdaq Capital Market or consider actions such as a reverse stock split, and it can appeal any delisting determination. For now, its stock continues to trade on the Nasdaq Global Select Market under the symbol QNCX.
Quince Therapeutics filed an 8-K outlining a failed lead drug program, a shift to strategic alternatives, and heightened financial risk. As of December 31, 2025, it preliminarily estimates $5.8 million in cash and cash equivalents, $11.9 million in short-term investments, and $16.4 million outstanding under its EIB Loan.
The company’s lead candidate eDSP failed to meet primary and secondary endpoints in the NEAT clinical trial, leaving no current product candidates or meaningful operations. Management has engaged LifeSci Capital to evaluate strategic options, focusing on a potential reverse merger, but notes there are no agreements in place and no assurance of success.
Quince warns that the only opportunity for shareholder return now depends on completing a reverse merger. It highlights risks including potential Nasdaq delisting due to its share price being below $1.00 since January 29, 2026, possible acceleration of the EIB Loan upon a Material Adverse Change, and a scenario where failure to execute a transaction could lead to bankruptcy proceedings in which common stockholders likely receive no value.
Quince Therapeutics, Inc. reported that five members of its Board of Directors — Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray — resigned effective January 30, 2026. The company states these resignations were not due to any disagreement over operations, policies, or practices.
Quince Therapeutics, Inc. filed a current report to note that it has released top-line clinical data from a major late-stage study. On January 29, 2026, the company issued a press release with results from its pivotal Phase 3 NEAT clinical trial of eDSP in ataxia-telangiectasia, a serious inherited disorder. The press release, attached as Exhibit 99.1, contains the detailed trial outcomes and is incorporated by reference into this report.
Quince Therapeutics, Inc. filed a current report to note that it has announced its financial results for the quarter ended September 30, 2025 and shared recent business highlights. The company states that these details are contained in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to this report rather than being fully included in the body of the document.
Quince Therapeutics (QNCX) filed an 8-K under Regulation FD to correct an Investor Day statement. The company removed Slide 57 and the related video from its October 2, 2025 Virtual Investor Day and advised investors not to rely on the slide’s claim that IntraBio’s N-acetyl-L-leucine (NALL) “failed Phase 2 A-T study across all endpoints.”
Quince clarified its statement drew from a European Journal of Paediatric Neurology article describing a single-site study in ataxia-telangiectasia, which reported no significant improvements in ataxia symptoms or motor function, and was not the multi-site IntraBio Phase 2 Study.
Quince Therapeutics, Inc. reports an amendment to its unsecured credit facility with the European Investment Bank. For the period from January 1, 2026 to March 31, 2026, the company’s required minimum cash balance under the EIB Facility will be reduced from EUR 14,650,000 to EUR 5,000,000, temporarily easing its cash covenant. During this same period, out of the overall 9% Deferred Interest Rate on Tranche A and Tranche B, 1% will be converted into a Fixed Rate to be paid on March 31, 2026 on those tranches. The full amendment will be filed as an exhibit to the company’s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.
Quince Therapeutics, Inc. reported that on August 11, 2025 it announced its financial results for the quarter ended June 30, 2025 and provided recent business highlights. The company states the related press release is furnished as Exhibit 99.1 to this Current Report. The filing explicitly says the information (including Exhibit 99.1) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act. No financial figures or business-detail text from the press release are included in the provided document. The report is signed by Dirk Thye, Chief Executive Officer and Chief Medical Officer.